# Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy

> **NCT07721025** · PHASE2 · RECRUITING · sponsor: **Lexeo Therapeutics** · enrollment: 26 (estimated)

## Conditions studied

- Friedreich Ataxia
- Cardiomyopathy, Secondary

## Interventions

- **GENETIC:** LX2006
- **OTHER:** Usual Care

## Key facts

- **NCT ID:** NCT07721025
- **Lead sponsor:** Lexeo Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-25
- **Primary completion:** 2032-06
- **Final completion:** 2032-06
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2026-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07721025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07721025, "Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07721025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*